

# HEPATITIS C VIRUS TREATMENTS (Part 1 of 2)

Hepatitis C virus (HCV) management for treatment-naïve patients is based on HCV genotype and the presence or absence of cirrhosis. The following lists the recommended treatments and duration of therapy for genotypes 1 through 6. For management of treatment-experienced patients or those with multiple treatment failures, please refer to the AASLD-IDSA's HCV guidelines or the full drug labeling.

Genotype	Without Cirrhosis	With Compensated Cirrhosis	With Decompensated Cirrhosis <sup>1</sup>
<b>TREATMENT NAÏVE</b>			
Genotype 1a	<ul style="list-style-type: none"> <li>Mavyret for 8wks <b>OR</b></li> <li>Harvoni for 12wks<sup>2</sup> <b>OR</b></li> <li>Epclusa for 12wks</li> </ul> <i>Alternative:</i> <ul style="list-style-type: none"> <li>Zepatier for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>Harvoni for 12wks <b>OR</b></li> <li>Epclusa for 12wks <b>OR</b></li> <li>Mavyret for 8wks</li> </ul> <i>Alternative:</i> <ul style="list-style-type: none"> <li>Zepatier for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>Harvoni + ribavirin<sup>4</sup> for 12wks <b>OR</b></li> <li>Epclusa + ribavirin<sup>6</sup> for 12wks <b>OR</b></li> <li>Harvoni for 24wks <b>OR</b></li> <li>Epclusa for 24wks</li> </ul>
Genotype 1b	<ul style="list-style-type: none"> <li>Zepatier for 12wks<sup>5</sup> <b>OR</b></li> <li>Mavyret for 8wks <b>OR</b></li> <li>Harvoni for 12wks<sup>2,7</sup> <b>OR</b></li> <li>Epclusa for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>Zepatier for 12wks <b>OR</b></li> <li>Harvoni for 12wks <b>OR</b></li> <li>Epclusa for 12wks <b>OR</b></li> <li>Mavyret for 8wks</li> </ul>	<ul style="list-style-type: none"> <li>Harvoni + ribavirin<sup>4</sup> for 12wks <b>OR</b></li> <li>Epclusa + ribavirin<sup>6</sup> for 12wks <b>OR</b></li> <li>Harvoni for 24wks <b>OR</b></li> <li>Epclusa for 24wks</li> </ul>
Genotype 2	<ul style="list-style-type: none"> <li>Mavyret for 8wks <b>OR</b></li> <li>Epclusa for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>Epclusa for 12wks <b>OR</b></li> <li>Mavyret for 8wks</li> </ul>	<ul style="list-style-type: none"> <li>Epclusa + ribavirin<sup>6</sup> for 12wks <b>OR</b></li> <li>Epclusa for 24wks</li> </ul>
Genotype 3	<ul style="list-style-type: none"> <li>Mavyret for 8wks <b>OR</b></li> <li>Epclusa for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>Mavyret for 8wks <b>OR</b></li> <li>Epclusa for 12wks<sup>3</sup></li> </ul> <i>Alternative:</i> <ul style="list-style-type: none"> <li>Epclusa + ribavirin for 12wks<sup>3</sup> <b>OR</b></li> <li>Vosevi for 12wks<sup>3</sup></li> </ul>	<ul style="list-style-type: none"> <li>Epclusa + ribavirin<sup>6</sup> for 12wks <b>OR</b></li> <li>Epclusa for 24wks</li> </ul>
Genotype 4	<ul style="list-style-type: none"> <li>Zepatier for 12wks <b>OR</b></li> <li>Mavyret for 8wks <b>OR</b></li> <li>Harvoni for 12wks<sup>9</sup> <b>OR</b></li> <li>Epclusa for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>Epclusa for 12wks <b>OR</b></li> <li>Mavyret for 8wks<sup>5</sup> <b>OR</b></li> <li>Zepatier for 12wks <b>OR</b></li> <li>Harvoni for 12wks</li> </ul>	<ul style="list-style-type: none"> <li>Harvoni + ribavirin<sup>4</sup> for 12wks <b>OR</b></li> <li>Epclusa + ribavirin<sup>6</sup> for 12wks <b>OR</b></li> <li>Harvoni for 24wks <b>OR</b></li> <li>Epclusa for 24wks</li> </ul>
Genotypes 5 or 6	<ul style="list-style-type: none"> <li>Mavyret for 8wks <b>OR</b></li> <li>Epclusa for 12wks <b>OR</b></li> <li>Harvoni for 12wks<sup>9</sup></li> </ul>	<ul style="list-style-type: none"> <li>Mavyret for 8wks <b>OR</b></li> <li>Epclusa for 12wks <b>OR</b></li> <li>Harvoni for 12wks<sup>9</sup></li> </ul>	<ul style="list-style-type: none"> <li>Harvoni + ribavirin<sup>4</sup> for 12wks <b>OR</b></li> <li>Epclusa + ribavirin<sup>6</sup> for 12wks <b>OR</b></li> <li>Harvoni for 24wks <b>OR</b></li> <li>Epclusa for 24wks</li> </ul>

## PHARMACOLOGICAL THERAPIES

Generic	Brand	Strength	Form	Dose
elbasvir/grazoprevir	<b>Zepatier</b>	50mg/100mg	tabs	<b>Adults and Children: &lt;12yrs (&lt;30kg): not established. ≥12yrs or ≥30kg:</b> 1 tab once daily.
glecaprevir/pibrentasvir	<b>Mavyret</b>	100mg/40mg	tabs	<b>Adults and Children: &lt;3yrs: not established. ≥3yrs (&lt;20kg):</b> 150mg/60mg (pellets) once daily; (20–<30kg): 200mg/80mg (pellets) once daily; (30–<45kg): 250mg/100mg (pellets) once daily; (≥45kg): 300mg/120mg (tabs or pellets) once daily. <b>≥12yrs:</b> 300mg/120mg (tabs or pellets) once daily.
	<b>Mavyret Oral Pellets</b>	50mg/20mg	pellets	
ledipasvir/sofosbuvir	<b>Harvoni</b>	45mg/200mg, 90mg/400mg	tabs	<b>Adults:</b> 90mg/400mg (tabs) once daily. <b>Children: &lt;3yrs: not established. ≥3yrs (&lt;17kg):</b> 33.75mg/150mg (pellets) once daily; (17–<35kg): 45mg/200mg (tabs or pellets) once daily; (≥35kg): 90mg/400mg (tabs or pellets) once daily.
	<b>Harvoni Oral Pellets</b>	33.75mg/150mg, 45mg/200mg	pellets	
ribavirin	—	200mg	caps, tabs	<b>Adults:</b> Take with food in 2 divided doses. <b>≥18yrs (&lt;75kg):</b> 1g/day; (≥75kg): 1.2g/day. <i>Low initial dose:</i> 600mg; increase as tolerated. <b>Children: &lt;3yrs: not established.</b> Take with food in 2 divided doses. <b>≥3yrs (&lt;47kg):</b> 15mg/kg/day; (47–49kg): 600mg/day; (50–65kg): 800mg/day; (66–80kg): 1g/day; (>80kg): 1.2g/day. <i>Low initial dose:</i> 600mg; increase as tolerated.
sofosbuvir	<b>Sovaldi</b>	200mg, 400mg	tabs	<b>Adults:</b> 400mg (tabs) once daily. <b>Children: &lt;3yrs: not established. ≥3yrs (&lt;17kg):</b> 150mg (pellets) once daily; (17–<35kg): 200mg (tabs or pellets) once daily; (≥35kg): 400mg (tabs or pellets) once daily.
	<b>Sovaldi Oral Pellets</b>	150mg, 200mg	pellets	
sofosbuvir/velpatasvir	<b>Epclusa</b>	200mg/50mg, 400mg/100mg	tabs	<b>Adults:</b> 400mg/100mg (tabs) once daily. <b>Children: &lt;3yrs: not established. ≥3yrs (&lt;17kg):</b> 150mg/37.5mg (pellets) once daily; (17–<30kg): 200mg/50mg (tabs or pellets) once daily; (≥30kg): 400mg/100mg (tabs or pellets) once daily.
	<b>Epclusa Oral Pellets</b>	150mg/37.5mg, 200mg/50mg	pellets	
sofosbuvir/velpatasvir/voxilaprevir	<b>Vosevi</b>	400mg/100mg/100mg	tabs	<b>Adults:</b> 1 tab once daily with food. <b>Children: Not established.</b>

## NOTES

- Key:** AASLD-IDSA = American Association for the Study of Liver Diseases and Infectious Diseases Society of America; HCV = hepatitis C virus; PI = protease inhibitor
- <sup>1</sup> Includes Child-Turcotte-Pugh (CTP) class B and class C patients who may or may not be candidates for liver transplantation, including those with hepatocellular carcinoma. Any protease inhibitor-containing regimen (eg, glecaprevir, grazoprevir, voxilaprevir) and interferon-based regimens are not recommended.
  - <sup>2</sup> An 8-week duration is recommended for treatment-naïve patients without cirrhosis who are HIV uninfected, and whose HCV RNA level is <6 million IU/ml.
  - <sup>3</sup> Baseline NS5A RAS Y93H testing for velpatasvir is recommended. If baseline NS5A RAS Y93H is present, ribavirin should be added to the regimen, or change regimen to Vosevi.
  - <sup>4</sup> Initiate with low-dose ribavirin (600mg) and increase as tolerated to weight-based dosing.
  - <sup>5</sup> Duration of 12 weeks is recommended for HIV/HCV co-infection.
  - <sup>6</sup> With weight-based ribavirin. For patients with CTP class C cirrhosis, initiate with low-dose ribavirin (600mg) and increase as tolerated.
  - <sup>7</sup> Consider an 8-week regimen in patients with genotype 1b and mild fibrosis.
  - <sup>8</sup> Consider an 8-week regimen in patients with favorable baseline characteristics (eg, no cirrhosis, HCV RNA <6 million IU/mL, absence of genotype 4r).
  - <sup>9</sup> Not recommended for genotype 6 if subtype is known.
  - <sup>10</sup> Consider extending treatment to 24 weeks in extremely difficult cases (eg, genotype 3 with cirrhosis or failure following Mavyret + Sovaldi regimen).
  - <sup>11</sup> Not recommended in patients with prior exposure to an NS5A inhibitor plus NS3/4 PI regimens (eg, elbasvir/grazoprevir).
- Not an inclusive list of medications and/or official indications. Please see drug monograph at [www.eMPR.com](http://www.eMPR.com) and/or contact company for full drug labeling.

## REFERENCES

AASLD-IDSA. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. <http://www.hcvguidelines.org>. Updated October 24, 2022. Accessed October 27, 2022.